Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway

Psychiatry Research

Volumn 196, Issue 2-3, 2012, Pages 243-249

  Maes, Michael ^a   Rief, Winfried ^b  

^a Maes Clinics at Tria   (Thailand)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cytokines; Depression; Inflammation; Serotonin; Somatization; Tryptophan

Indexed keywords

BIOLOGICAL MARKER; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATTERN RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RATING SCALE; SCORING SYSTEM; SOMATIZATION; SYMPTOM CHECKLIST 90; TRYPTOPHAN BRAIN LEVEL;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DEPRESSION; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; SOMATOFORM DISORDERS; TRYPTOPHAN;

EID: 84861484035     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.09.029     Document Type: Article

References (79)

1. Abbey S.E. Somatization and somatoform disorders. Textbook of Consultation-Liaison Psychiatry 1996, The American Psychiatric Press, Washington DC. J.R. Rundell, M.G. Wise (Eds.).
2. Aldenderfer M.S., Blashfield R.K. Validation techniques. Cluster Analysis 1986, 62-73. Sage Publications, London.
3. Alonso Fernández F. Somatoform depressive disorders. Anales de la Real Academia Nacional de Medicina 2001, 118(4):745-766.
4. Ballenger P.C. Panic disorder in the medical setting. The Journal of Clinical Psychiatry 1997, 58(Suppl. 2):13-17.
5. Beck A.T., Ward C.H., Medelson M., Mock F., Erbaugh F. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
6. Beneke M. Methodological investigations of the Hamilton Anxiety Scale. Pharmacopsychiatry 1987, 20:249-255.
7. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Verkerk R., Meltzer H., Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Journal of Clinical Psychopharmacology 2002, 22(1):86-90.
8. Booij L., Swenne C.A., Brosschot J.F., Haffmans P.M., Thayer J.F., Van der Does A.J. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biological Psychiatry 2006, 60(5):507-514.
9. Brown F.W., Golding J.M., Smith G.R. Psychiatric comorbidity in primary care somatization disorder. Psychosomatic Medicine 1990, 52(4):445-551.
10. Bschor T. Masked depression: the rise and fall of a diagnosis. Psychiatrische Praxis 2002, 29(4):207-210.
11. Cairns B.E., Svensson P., Wang K., Hupfeld S., Graven-Nielsen T., Sessle B.J., Berde C.B., Arendt-Nielsen L. Activation of peripheral NMDA receptors contributes to human pain and rat afferent discharges evoked by injection of glutamate into the masseter muscle. Journal of Neurophysiology 2003, 90(4):2098-2105.
12. DeMyer M.K., Shea P.A., Hendrie H.C., Yoshimura N.N. Plasma tryptophan and five other amino acids in depressed and normal subjects. Archives of General Psychiatry 1981, 38(6):642-646.
13. Derde M.P., Massart D.L. Extraction of information from large data sets by pattern recognition. Fresenius Zeitschrift fur Analytische Chemistry 1982, 313:484-495.
14. Derogatis L.R. Symptom Checklist-90-R. Administration, Scoring, and Procedures Manual 1994, National Computer Systems, Minneapolis. ed 3.
15. Drummond P.D. Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers. Cephalalgia 2006, 26(10):1225-1233.
16. Escobar J.I., Burnam M.A., Karno M., Forsythe A., Golding J.M. Somatization in the community. Archives of General Psychiatry 1987, 44(8):713-718.
17. Escobar J.I., Rubio-Stipec M., Canino G., Karno M. Somatic symptoms index (SSI): a new and abridged somatization construct - prevalence and epidemiological correlates in two large community samples. Journal of Nervous and Mental Disorders 1989, 177:140-146.
18. Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. Journal of Chronic Diseases 1970, 23:455-468.
19. First M.B. Mutually exclusive versus co-occurring diagnostic categories: the challenge of diagnostic comorbidity. Psychopathology 2005, 38(4):206-210.
20. Fisch R.Z. Masked depression: its interrelations with somatization, hypochondriasis and conversion. International Journal of Psychiatry in Medicine 1987, 17(4):367-379.
21. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., Babb J.S., Hirsch G.S., Liebes L. The possible role of the kynurenine pathway in adolescent depression with melancholic features. Journal of Child Psychology and Psychiatry 2010, 51(8):935-943.
22. Hamilton M. The assessment of anxiety by rating. The British Journal of Psychiatry 1959, 32:50-55.
23. Hervé C., Beyne P., Jamault H., Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. Journal of Chromatography. B Biomedical Applications 1996, 675(1):157-161.
24. Hiller W., Zaudig M., Mombour W. International Diagnostic Check Lists for ICD-10 and DSM-IV 1997, Huber, Bern.
25. Joseph M.S., Brewerton T.D., Reus V.I., Stebbins G.T. Plasma l-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Research 1984, 11(3):185-192.
26. Kaszaki J., Palásthy Z., Erczes D., Rácz A., Torday C., Varga G., Vécsei L., Boros M. Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterology and Motility 2008, 20(1):53-62.
27. Katon W., Russo J. Somatic symptoms and depression. The Journal of Family Practice 1989, 29(1):65-69.
28. Katon W., Kleinman A., Rosen G. Depression and somatization: a review. Part I. The American Journal of Medicine 1982, 72(1):127-135.
29. Katon W., Lin E., Von Korff M., Russo J., Lipscomb P., Bush T. Somatization: a spectrum of severity. American Journal of Psychiatry 1991, 148(1):34-40.
30. Kékesi G., Horváth G. Analgesic effect of kynurenic acid. Ideggyógyászati Szemle 2002, 55(9-10):313-322.
31. Kilkens T.O., Honig A., van Nieuwenhoven M.A., Riedel W.J., Brummer R.J. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004, 53(12):1794-1800.
32. Kirmayer L.J., Dao T.H.T., Smith A. Somatization and psychologization: understanding cultural idioms of distress. Clinical Methods in Transcultural Psychiatry 1998, 233-265. American Psychiatric Press, Washington DC. S. Okpaku (Ed.).
33. Kroenke K., Spitzer R.L., deGruy F.V., Hahn S.R., Linzer M., Williams J.B., Brody D., Davies M. Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Archives of General Psychiatry 1997, 54(4):352-358.
34. Lapin I.P. Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. Journal of Psychopharmacology 1996, 10(3):246-249.
35. Lapin I.P. Antagonism of kynurenic acid to anxiogens in mice. Life Sciences 1998, 63(15):PL231-PL236.
36. Lipowski Z.J. Somatization and depression. Psychosomatics 1990, 31(1):13-21.
37. Löwe B., Spitzer R.L., Williams J.B., Mussell M., Schellberg D., Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. General Hospital Psychiatry 2008, 30(3):191-199.
38. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuropsychopharmacology and Biological Psychiatry 1995, 19(1):11-38.
39. Maes M. "Functional" or "psychosomatic" symptoms, e.g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinology Letters 2009, 30(5):564-573.
40. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Progress in Neuropsychopharmacology and Biological Psychiatry 2011, 35(3):664-675.
41. Maes M.H., De Ruyter M., Suy E. Prediction of subtype and severity of depression by means of dexamethasone suppression test, l-tryptophan: competing amino acid ratio, and MHPG flow. Biological Psychiatry 1987, 22(2):177-188.
42. Maes M., Schotte C., Maes L., Cosyns P. Clinical subtypes of unipolar depression: part II. Quantitative and qualitative clinical differences between the vital and nonvital depression groups. Psychiatry Research 1990, 34(1):43-57.
43. Maes M., Minner B., Suy E. The relationships between the availability of l-tryptophan to the brain, the spontaneous HPA-axis activity, and the HPA-axis responses to dexamethasone in depressed patients. Journal of Amino Acids 1991, 1(1):57-65.
44. Maes M., Maes L., Schotte C., Cosyns P. A clinical and biological validation of the DSM-III melancholia diagnosis in men: results of pattern recognition methods. Journal of Psychiatric Research 1992, 26(3):183-196.
45. Maes M., Meltzer H.Y., Scharpé S., Bosmans E., Suy E., De Meester I., Calabrese J., Cosyns P. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Research 1993, 49(2):151-165.
46. Maes M., Scharpé S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., Vanden Bossche B.V., Cosyns P. Increased neopterin and interferon-gamma secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response. Psychiatry Research 1994, 54(2):143-160.
47. Maes M., Wauters A., Verkerk R., Demedts P., Neels H., Van Gastel A., Cosyns P., Scharpe S., Desnyder R. Lower serum l-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism. Neuropsychopharmacology 1996, 15(3):243-251.
48. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Molecular Psychiatry 2001, 6(4):475-480.
49. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progress Neuropsychopharmacology and Biological Psychiatry 2011, 35(3):702-721. Epub 2010 Dec 23.
50. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, which may indicate increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinology Letters 2011, 32(3):264-273.
51. Massart L., Kaufman L. Nonhierarchical clustering methods. The Interpretation of Analytical Chemical Data by the Use of Cluster Analysis 1983, 101-138. John Wiley and Sons, New York. P.J. Elving, J.D. Winefordner (Eds.).
52. Mecs L., Tuboly G., Nagy E., Benedek G., Horvath G. The peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint model. Anesthesia and Analgesia 2009, 109(4):1297-1304.
53. Møller S.E. Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta Psychiatrica Scandinavica 1985, (Suppl. 325):3-31.
54. Mountjoy C.Q., Roth M. Studies in the relationship between depressive disorders and anxiety states: part 2: rating scales. Journal of Affective Disorders 1982, 4:127-147.
55. Myint A.M., Kim Y.K., Verkerk R., Scharpé S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. Journal of Affective Disorders 2007, 98(1-2):143-151.
56. Németh H., Toldi J., Vécsei L. Role of kynurenines in the central and peripheral nervous systems. Current Neurovascular Research 2005, 2(3):249-260.
57. Oxenkrug G.F. Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Annals of the New York Academy of Sciences 2007, 1122:35-49.
58. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Molecular Psychiatry 2010, 15(4):393-403.
59. Rief W., Fichter M. The Symptom Check List SCL-90-R and its ability to discriminate between dysthymia, anxiety disorders, and anorexia nervosa. Psychopathology 1992, 25(3):128-138.
60. Rief W., Hiller W. Toward empirically based criteria for the classification of somatoform disorders. Journal of Psychosomatic Research 1999, 46(6):507-518.
61. Rief W., Hiller W., Heuser J. SOMS - Das Screening für somatoforme Störungen. Manual zum Fragebogen 1997, Huber, Bern.
62. Rief W., Hessel A., Braehler E. Somatization symptoms and hypochondriacal features in the general population. Psychosomatic Medicine 2001, 63(4):595-602.
63. Rief W., Pilger F., Ihle D., Bosmans E., Egyed B., Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Research 2001, 105(3):165-174.
64. Rief W., Pilger F., Ihle D., Verkerk R., Scharpe S., Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 2004, 49(1):24-29.
65. Robbins J.M., Kirmayer L.J. Transient and persistent hypochondriacal worry in primary care. Psychological Medicine 1996, 26:575-589.
66. Schmitt M.L., Graeff F.G., Carobrez A.P. Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test. Brazilian Journal of Medicine and Biological Research 1990, 23(8):677-679.
67. Servan-Schreiber D., Kolb N.R., Tabas G. Somatizing patients: part I. Practical diagnosis. American Family Physician 2000, 61(4):1073-1078.
68. Sharaf M.A., Illman D.L., Kowalski B.R. Unsupervised learning. Chemometrics 1986, 219-228. John Wiley and Sons, New York.
69. Silverstein B. Gender differences in the prevalence of somatic versus pure depression: a replication. The American Journal of Psychiatry 2002, 159(6):1051-1052.
70. Simon G.E., VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. The American Journal of Psychiatry 1991, 148(11):1494-1500.
71. Simon G.E., VonKorff M., Piccinelli M., Fullerton C., Ormel J. An international study of the relation between somatic symptoms and depression. The New England Journal of Medicine 1999, 341(18):1329-1335.
72. Smith G.C., Clarke D.M., Handrinos D., Dunsis A., McKenzie D.P. Consultation-liaison psychiatrists' management of somatoform disorders. Psychosomatics 2000, 41(6):481-489.
73. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nature Reviews. Drug Discovery 2002, 1(8):609-620.
74. Struzik L., Duffin J., Vermani M., Hegadoren K., Katzman M.A. Effects of tryptophan depletion on central and peripheral chemoreflexes in man. Respiratory Physiology & Neurobiology 2002, 133(3):183-195.
75. Valderas J.M., Starfield B., Sibbald B., Salisbury C., Roland M. Defining comorbidity: implications for understanding health and health services. Annals of Family Medicine 2009, 7(4):357-363.
76. van Veen J.F., van Vliet I.M., de Rijk R.H., van Pelt J., Mertens B., Fekkes D., Zitman F.G. Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. Psychoneuroendocrinology 2009, 34(10):1590-1594.
77. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpé S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry 2005, 10(6):538-544.
78. Widner B., Sepp N., Kowald E., Ortner U., Wirleitner B., Fritsch P., Baier-Bitterlich G., Fuchs D. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000, 201(5):621-630.
79. Wittchen H.U., Schramm E., Zaudig M., Unland H. (SKID). Strukturiertes klinisches Interview für DSM-IV, Achse I, Deutsche Version 1997, Hogrefe, Göttingen.